跳至主要内容
临床试验/CTRI/2013/07/003838
CTRI/2013/07/003838已完成1 期

An Interventional, Placebo-controlled, Randomized, Double blinded, Dose comparison, Phase I/II Study to determine the safety and efficacy of a new gel formulation of Esmolol Hydrochloride (GALNOBAX®) for the treatment of Diabetic Foot Ulcer (DFU) - NI

ovalead Pharma Private Limited0 个研究点目标入组 50 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients having single or up to two ulcers, minimum 4.0 cm apart, below knee ulcer of at least 4 weeks and maximum of 52 weeks duration which is a full thickness ulcer without exposure of bone, muscle, ligaments, or tendons
  • Ulcer should be clinically non-infected as determined by clinical examination and complete hemogram
  • Ulcer area (length x width) measurement between 1.5 square centimeter and 10 square centimeter, inclusive and post debridement ulcer area less than or equal to 12 square centimeter
  • Full-thickness ulcer of Grade 1 or Grade 2 as per Wagnerâ??s classification system

排除标准

  • Actively infected ulcers with or without purulent discharge, ulcers with exposed bone or associated with osteomyelitis
  • Patients with target limb cellulitis, ischemic or gangrenous ulcers in the opinion of the Investigator

研究者

发起方
ovalead Pharma Private Limited

相似试验